Biomet, Inc. (NASDAQ:BMET) reports record sales and earnings
results today for its third quarter ended February 28, 2006. Net
sales increased 5% to $506,254,000. Operating income increased 9%
to $156,993,000 from $144,270,000 and increased 4%, on an adjusted
basis, from $151,672,000. Net income increased 10% to $106,065,000
from $96,784,000 and increased 4%, as adjusted, from $101,615,000.
Diluted earnings per share increased 13% to $0.43 from $0.38 and
increased 8%, on an adjusted basis, from $0.40. President and Chief
Executive Officer Dane A. Miller, Ph.D., stated, "Biomet's record
results during the third quarter of fiscal year 2006 are
attributable to continued solid sales growth for orthopedic
reconstructive devices, dental reconstructive implants and internal
fixation devices. Cost of goods sold was increased by approximately
$1.5 million during the quarter due to the previously announced
price increase from the supplier of Biomet's antibiotic delivery
system in Europe. Additionally, Biomet's national branding campaign
increased selling, general and administrative expenses by
approximately 60 basis points during the third quarter. We have
chosen to invest in Biomet's future growth through this awareness
program and we expect the expenses associated with the national
branding campaign to decrease in future quarters." Excluding the
impact of foreign currency, net sales increased 8% worldwide.
International revenues for the third quarter increased 11%, while
domestic revenues increased 6%. Unless otherwise noted, all of the
following percentages are quoted on a constant-currency basis.
During the third quarter of fiscal year 2006, reconstructive device
sales increased 10% worldwide to $346,610,000. Knee sales increased
8% in the United States during the third quarter and increased 9%
worldwide. Strong demand for Biomet's new knee products, including
total and unicompartmental systems, continued to drive growth
during the quarter. Hip sales increased 11% worldwide and in the
United States during the third quarter. Biomet's metal-on-metal
acetabular systems and titanium porous coated hip stems, as well as
second-generation highly crosslinked polyethylene components,
continued to receive excellent market acceptance. Extremity sales
increased 20% worldwide during the third quarter and 21% in the
United States. Dental reconstructive implant sales increased 16%
worldwide and 13% in the United States during the quarter. Sales of
bone cements and accessories decreased 8% worldwide during the
third quarter and decreased 10% in the United States. Fixation
sales increased 2% worldwide during the third quarter of fiscal
year 2006 to $62,338,000. Domestic fixation sales increased 1%
during the quarter. Internal fixation sales increased 15% in the
United States and 7% worldwide during the third quarter. Lorenz
Surgical's craniomaxillofacial fixation sales increased 5%
worldwide during the third quarter and increased 7% in the United
States. Electrical stimulation device sales increased 1% worldwide
and in the United States during the quarter. External fixation
sales decreased 10% worldwide during the third quarter and
decreased 12% in the United States. Spinal product sales increased
3% worldwide to $53,914,000 during the third quarter and increased
3% in the United States. Sales of spinal implants and
orthobiologics for the spine increased 9% worldwide and in the
United States during the third quarter, while spinal stimulation
sales decreased 4% worldwide and 3% in the United States. During
the third quarter, sales of the Company's "other products"
increased 8% worldwide to $43,392,000 and increased 4% in the
United States. Arthroscopy sales increased 12% worldwide during the
quarter and increased 7% in the United States. Sales of softgoods
and bracing products increased 2% worldwide and 4% in the United
States during the third quarter. Dr. Miller concluded, "Biomet
continues to experience market-leading growth in its reconstructive
device products segment despite extremely strong previous year
growth comparisons in the important knee product category. We are
pleased with the momentum of certain EBI product categories,
particularly internal fixation. In addition, electrical stimulation
device sales exhibited positive growth after several quarters of
declining sales, while spinal hardware and orthobiologic products
for the spine experienced an acceleration in growth. However, due
to the continued strength of the U.S. dollar, we estimate that
foreign currency will negatively affect fourth quarter sales by
approximately $11 million. Consequently, we remain comfortable with
analysts' sales and earnings estimates of $530 million to $540
million and $0.45 to $0.46 per share for the fourth quarter of
fiscal year 2006." Biomet, Inc. and its subsidiaries design,
manufacture and market products used primarily by musculoskeletal
medical specialists in both surgical and non-surgical therapy. The
Company's product portfolio encompasses reconstructive products,
including orthopedic joint replacement devices, bone cements and
accessories, and dental reconstructive implants; fixation products,
including electrical bone growth stimulators, internal and external
orthopedic fixation devices, craniomaxillofacial implants and bone
substitute materials; spinal products, including spinal stimulation
devices, spinal hardware and orthobiologics; and other products,
such as arthroscopy products and softgoods and bracing products.
Headquartered in Warsaw, Indiana, Biomet and its subsidiaries
currently distribute products in more than 100 countries. For
further information contact Greg W. Sasso, Vice President,
Corporate Development and Communications at (574) 372-1528 or
Barbara Goslee, Manager, Corporate Communications at (574)
372-1514. This press release contains certain statements that are
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, as amended. Although the Company believes
that the assumptions, on which the forward-looking statements
contained herein are based, are reasonable, any of those
assumptions could prove to be inaccurate given the inherent
uncertainties as to the occurrence or non-occurrence of future
events. There can be no assurance that the forward-looking
statements contained in this press release will prove to be
accurate. Some of the factors that could cause actual results to
differ from those contained in forward-looking statements made in
this press release include the success of the Company's principal
product lines and reorganization efforts with respect to its EBI
operations, the Company's ability to develop and market new
products and technologies in a timely manner, government
regulation, currency exchange rate fluctuations, reimbursements
from third party payors, litigation, revenue and earnings
estimates, and other risk factors as set forth from time to time in
the Company's filings with the SEC. The inclusion of a
forward-looking statement herein should not be regarded as a
representation by the Company that the Company's objectives will be
achieved. The Company undertakes no obligation to publicly update
forward-looking statements, whether as a result of new information,
future events or otherwise. All of Biomet's financial information
may be obtained on our website at www.biomet.com or you may contact
us by e-mail at investor.relations@biometmail.com. All trademarks
are owned by Biomet, Inc., or one of its subsidiaries. -0- *T
BIOMET, INC. RESULTS FOR THE QUARTERS ENDED FEBRUARY 28 (in
thousands, except per share data) Three Months Ended Nine Months
Ended ----------------------- ----------------------- 2006 2005
2006 2005 ----------- ----------- ----------- ----------- Net Sales
$506,254 $482,023 $1,485,847 $1,376,857 Cost of Sales 143,061
130,666 417,167 373,349 Cost of Sales, current period impact of
inventory step-up -- 7,402 -- 21,806 ----------- -----------
----------- ----------- Gross Profit 363,193 343,955 1,068,680
981,702 S, G, & A 185,137 179,224 544,772 505,989 R & D
21,063 20,461 63,182 58,543 In-process research and development --
-- -- 26,020 ----------- ----------- ----------- -----------
Operating Income 156,993 144,270 460,726 391,150 Other Income
(Expense), Net 2,262 2,641 2,575 2,157 ----------- -----------
----------- ----------- Income Before Taxes And Minority Interest
159,255 146,911 463,301 393,307 Income Taxes 53,190 52,698 155,659
152,465 Income Taxes related to inventory step-up -- (2,571) --
(7,574) ----------- ----------- ----------- ----------- Net Income
106,065 96,784 307,642 248,416 =========== =========== ===========
=========== Earnings per Share Basic .43 .38 1.24 .98 Diluted .43
.38 1.23 .97 Basic Shares Outstanding 246,859 252,182 248,270
253,000 Diluted Shares Outstanding 247,772 253,993 249,202 255,029
U.S. sales $332,678 $313,204 $975,605 $918,514 Foreign sales
173,576 168,819 510,242 458,343 Reconstructive sales $346,610
$326,220 $1,006,764 $910,087 Fixation sales 62,338 62,090 187,192
185,131 Spinal product sales 53,914 52,615 164,267 158,756 Other
product sales 43,392 41,098 127,624 122,883 Consolidated Balance
Sheets February 28, 2006 May 31, 2005 Assets Cash and Investments
$169,836 $177,074 Accounts and notes receivable, net 498,761
479,745 Inventories 523,323 469,791 Other current assets 117,402
108,712 Fixed Assets, net 340,872 322,887 Goodwill 432,966 435,621
Other Assets 94,807 102,747 ----------------- -----------------
Total Assets $2,177,967 $2,096,577 =================
================= Liabilities and Stockholders' Equity Current
Liabilities $506,202 $501,391 Other Liabilities 29,195 31,255
Stockholders' Equity 1,642,570 1,563,931 -----------------
----------------- Total Liabilities and Stockholders' Equity
$2,177,967 $2,096,577 ================= =================
Management uses non-GAAP financial measures, such as net sales,
excluding the impact of foreign currency, operating income as
adjusted, net income as adjusted, and diluted earning per share as
adjusted. The term "as adjusted", a non-GAAP financial measure,
refers to financial performance measures that exclude the following
charges: (a) the impact of inventory step-up related to the
acquisition of the interest of Merck KGaA in the Biomet Merck joint
venture and Interpore International, Inc.; (b) in-process research
and development written off as of the closing date related to the
acquisition of the interest of Merck KGaA in the Biomet Merck joint
venture and Interpore International, Inc.; and (c) tax effect of
item (a) above. Inventory stepped-up to its current fair market
value in an acquisition and subsequently sold, results in a higher
cost of goods sold during the periods in which the stepped-up
inventory is sold, thus overstating cost of goods sold and
understating gross margins versus historical and future periods in
which the inventory sold represents the actual cost of products
manufactured. In-process research and development written off as of
the closing date of an acquisition is a one-time event that is not
indicative of future results. The Company's management believes
that the presentation of these measures provides useful information
to investors. These measures may assist investors in evaluating the
Company's operations, period over period. Management uses these
measures internally for evaluation of the performance of the
business, including the allocation of resources and the evaluation
of results relative to team member performance compensation
targets. Investors should consider these non-GAAP measures only as
a supplement to, not as a substitute for or as superior to,
measures of financial performance prepared in accordance with GAAP.
BIOMET, INC. Reconciliation of non-GAAP financial information to
GAAP financial information RESULTS FOR THE QUARTERS ENDED FEBRUARY
28, 2005 (last year) (in thousands, except per share data) Three
Months Nine Months --------------------- ---------------------
Percent of Percent of Amount Sales Amount Sales ----------
---------- ---------- ---------- Operating income, as reported
$144,270 29.9% $391,150 28.4% Inventory step-up (a) 7,402 1.5
21,806 1.6 In-process research and development (b) -- -- 26,020 1.9
---------- ---------- ---------- ---------- Operating income, as
adjusted $151,672 31.4% $438,976 31.9% Net income, as reported
$96,784 20.1% $248,416 18.0% Inventory step-up (a) 7,402 1.5 21,806
1.6 In-process research and development (b) -- -- 26,020 1.9 Tax
effect of inventory step-up (c) (2,571) (0.5) (7,574) (0.5)
---------- ---------- ---------- ---------- Net income, as adjusted
$101,615 21.1% $288,668 21.0% Three Months Nine Months
--------------------- --------------------- Basic Diluted Basic
Diluted ---------- ---------- ---------- ---------- Earnings per
share, as reported $0.38 $0.38 $0.98 $0.97 Inventory step-up (a)
0.03 0.03 0.09 0.09 In-process research and development (b) -- --
0.10 0.10 Tax effect of inventory step-up (c) (0.01) (0.01) (0.03)
(0.03) ---------- ---------- ---------- ---------- Earnings per
share, as adjusted $0.40 $0.40 $1.14 $1.13 Current year sales
growth as reported and in local currencies is as follows: Sales
Sales Sales Sales Growth Growth in Growth Growth in As FX Local As
FX Local Reported Impact Currencies Reported Impact Currencies
Three Months Nine Months ---------------------------
--------------------------- U.S. sales 6% 0% 6% 6% 0% 6% Foreign
sales 3 8 11 11 2 13 Total sales 5 3 8 8 1 9 Reconstructive sales
6% 4% 10% 11% 0% 11% Fixation sales 0 2 2 1 0 1 Spinal product
sales 2 1 3 3 0 3 Other product sales 6 2 8 4 0 4 *T
Biomet (NASDAQ:BMET)
Historical Stock Chart
From Jun 2024 to Jul 2024
Biomet (NASDAQ:BMET)
Historical Stock Chart
From Jul 2023 to Jul 2024